VSTMVerastem, Inc.

Nasdaq verastem.com


$ 3.46 $ -0.19 (-5.19 %)    

Friday, 14-Jun-2024 15:58:00 EDT
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 3.47
$ 3.57
$ 0.00 x 0
$ 0.00 x 0
$ 3.46 - $ 3.64
$ 3.27 - $ 14.22
364,636
na
0
$ 1.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-14-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-14-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 03-28-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-02-2021 06-30-2021 10-Q
13 05-11-2021 03-31-2021 10-Q
14 03-18-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-11-2020 12-31-2019 10-K
19 10-30-2019 09-30-2019 10-Q
20 08-01-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-12-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-03-2018 03-31-2018 10-Q
26 03-13-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-08-2017 06-30-2017 10-Q
29 05-10-2017 03-31-2017 10-Q
30 03-23-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-08-2016 06-30-2016 10-Q
33 05-09-2016 03-31-2016 10-Q
34 03-03-2016 12-31-2015 10-K
35 11-09-2015 09-30-2015 10-Q
36 08-10-2015 06-30-2015 10-Q
37 05-11-2015 03-31-2015 10-Q
38 03-10-2015 12-31-2014 10-K
39 10-30-2014 09-30-2014 10-Q
40 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 alliance-global-partners-maintains-buy-on-verastem-lowers-price-target-to-20

Alliance Global Partners analyst Jeff Grampp maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from $3...

 rbc-capital-maintains-outperform-on-verastem-lowers-price-target-to-16

RBC Capital analyst Gregory Renza maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $32 to...

 hc-wainwright--co-reiterates-buy-on-verastem-maintains-175-price-target

HC Wainwright & Co. analyst Sean Lee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $17.5 price target.

 whats-going-on-with-mid-cap-cancer-focused-verastem-oncology-stock-on-friday

Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in ...

 verastem-oncology-begins-fda-submission-for-accelerated-approval-of-new-cancer-treatment-seeks-priority-review-for-innovative-ovarian-cancer-drug-combo

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, tod...

 hc-wainwright--co-reiterates-buy-on-verastem-maintains-175-price-target

HC Wainwright & Co. analyst Sean Lee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $17.5 price target.

 verastem-q1-2024-gaap-eps-126-misses-094-estimate

Verastem (NASDAQ:VSTM) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(0.94) by...

 hc-wainwright--co-reiterates-buy-on-verastem-maintains-175-price-target

HC Wainwright & Co. analyst Sean Lee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $17.5 price target.

 rbc-capital-reiterates-outperform-on-verastem-maintains-32-price-target

RBC Capital analyst Gregory Renza reiterates Verastem (NASDAQ:VSTM) with a Outperform and maintains $32 price target.